Kinetiq zeigt starke fruehe Reife mit rund USD one billion kHYPE TVL und ueber 80% Hyperliquid LST Share. Bis HIP three Markets, Launch, KIP one Buybacks und sKNTQ Revenue bewiesen sind, bleiben Konzentrationsrisiken.
Investment View
Kinetiq sollte nach Validator Allocation, sKNTQ Buyback, HIP three Launch Revenue und externem Vault Risiko bewertet werden.
YouTube paid members only
This report slide deck is available only to paid members of the BCELAB YouTube channel. Join the channel on YouTube, then verify your membership here to view the slides.
Report Type
Project Maturity Analysis
Version
v1
Analysis Date
17. Juli 2026
Language
de
Disclaimer: This report is generated through AI-powered analysis and market data. This is not investment advice. All investment decisions should be made at your own risk.